News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
FDA
Almirall Gets FDA Approval for Migraine Drug
June 3, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- Spanish pharmaceutical firm Almirall on Wednesday said its Almotriptan migraine drug had gained U.S. Food and Drug Administration approval for adolescents.
Twitter
LinkedIn
Facebook
Email
Print
FDA
Approvals
Asia
Europe
MORE ON THIS TOPIC
Drug Development
Newron reveals 5 deaths in late-stage schizophrenia program as FDA maintains hold
October 8, 2026
·
2 min read
·
Gabrielle Masson
Insights
Beyond equity: Why venture debt is reshaping European biotech
October 8, 2026
·
1 min read
·
Jennifer C. Smith-Parker
Manufacturing
FDA extends review of Novo’s hemophilia A drug, citing manufacturing issues
October 6, 2026
·
2 min read
·
Gabrielle Masson
Opinion
FDA must ensure American patients can access new and experimental drugs
October 5, 2026
·
7 min read
·
Houman David Hemmati
